Ribonucleoprotein Assembly Defects Correlate with Spinal Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs
Francesca Gabanella, Matthew E. R. Butchbach, Luciano Saieva et al. · 2007
Read Ribonucleoprotein Assembly Defects Correlate with Spinal Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs by Francesca Gabanella, Matthew E. R. Butchbach, Luciano Saieva et al. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0000921.txt.
Introduction
Francesca Gabanella, Matthew Butchbach, Luciano Saieva and co-authors linked faulty particle assembly to severity in spinal muscular atrophy, for PLOS ONE in 2007. The disease weakens motor neurons and is caused by low levels of a protein called SMN. SMN works with partner proteins to assemble small nuclear ribonucleoproteins, machines the cell needs to process its messages.
The team asked whether how badly assembly fails matches how severe the disease is. They also found the defect hits a subset of those particles hardest. A match between a lab defect and real severity supports the idea that failed assembly drives the illness. It also points to where a therapy would need to act.
Catalog record
| CREATOR | Francesca Gabanella, Matthew E. R. Butchbach, Luciano Saieva et al. |
|---|---|
| YEAR | 2007 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000921
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Ribonucleoprotein Assembly Defects Correlate with Spinal Muscular Atrophy Severity and Preferentially Affect a Subset of Spliceosomal snRNPs Authors: Francesca Gabanella, Matthew E. R. Butchbach, Luciano Saieva, Claudia Carissimi, Arthur H. M. Burghes, Livio Pellizzoni Published: 2007, PLOS ONE DOI: 10.1371/journal.pone.0000921 ABSTRACT Spinal muscular atrophy (SMA) is a motor neuron disease caused by reduced levels of the survival motor neuron (SMN) protein. SMN together with Gemins2-8 and unrip proteins form a macromolecular complex that functions in the assembly of small nuclear ribonucleoproteins (snRNPs) of both the major and the minor splicing pathways. It is not known whether the levels of spliceosomal snRNPs are decreased in SMA. Here we analyzed the consequence of SMN deficiency on snRNP metabolism in the spinal cord of mouse models of SMA with differing phenotypic severities. We demonstrate that the expression of a subset of Gemin proteins and snRNP assembly activity are dramatically reduced in the spinal cord of severe SMA mice. Comparative analysis of different tissues highlights a similar decrease in SMN levels and a strong impairment of snRNP assembly in tissues of severe SMA mice, although the defect appears smaller in kidney than in neural tissue. We further show that the extent of reduction in both Gemin proteins expression and snRNP assembly activity in the spinal cord of SMA mice correlates with disease severity. Remarkably, defective SMN complex function in snRNP assembly causes a significant decrease in the levels of a subset of snRNPs and preferentially affects the accumulation of U11 snRNP—a component of the minor spliceosome—in tissues of severe SMA mice. Thus, impairment of a ubiquitous function of SMN changes the snRNP profile of SMA tissues by unevenly altering the normal proportion of endogenous snRNPs. These findings are consistent with the hypothesis that SMN deficiency affects the splicing machinery and in particular the minor splicing pathway of a rare class of introns in SMA. INTRODUCTION Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by degeneration of motor neurons in the spinal cord and skeletal muscle atrophy. SMA is the leading genetic cause of death in infancy and is classified into three types based on the age of onset and clinical severity [1] – [5] . Type I is the most severe and frequent form of SMA with disease onset before six months of age and death usually by the age of two. Type II is the intermediate form with onset prior to eighteen months and patients never gaining the ability to walk. Type III is the mild form characterized by onset after eighteen months with the ability to walk and a normal life expectancy. Very severe fetal-onset (type 0) and very mild adult-onset (type IV) forms of SMA have also been described. Irrespective of disease severity, all SMA patients have homozygous deletions or mutations in the survival motor neuron ( SMN1 ) gene, the SMA-determining gene, and retain at least one copy of the nearly identical SMN2 gene [6] . A single nucleotide difference functionally distinguishes SMN1 from SMN2 , affecting the amount of exon 7 inclusion in the SMN transcript [7] , [8] . The loss of exon 7 removes the carboxy-terminal amino acids making SMNΔ7 protein unstable and rapidly degraded [9] . As a consequence, the SMN2 gene produces low levels of full-length SMN and cannot compensate for the loss of SMN1 in SMA. However, the SMN2 gene copy number acts as a modifier of disease severity [10] , which inversely correlates with the levels of SMN expression in patients [11] , [12] . The SMN gene is ubiquitously expressed and is essential for viability in many organisms from yeast to humans. To understand SMA etiology and support therapeutics development, a number of different animal models of SMA have been created and SMA mice more closely resemble the feature of SMA pathology in humans [3] , [13] . Distinct strategies have been employed to circumvent the early embryonic lethality associated with the knockout of the single Smn gene in mice and generate mouse models of SMA [14] – [17] . Similar to the situation in the human disease, expression of the human SMN2 gene in the mouse Smn null background rescues embryonic lethality and results in mice with SMA [15] , [16] . Importantly, the severity of the phenotype is dependent on the SMN2 copy number. Severe SMA mice with a single SMN2 gene die embryonically while mice with two SMN2 copies survive on average for five days [15] , [16] . These mice have reduced weight and severe motor impairment before appreciable loss of motor neuron cell bodies, which occurs at postnatal day 3. Eight or more SMN2 gene copies fully rescue the SMA phenotype in SMA mice [16] . Interestingly, introducing a SMNΔ7 transgene that encodes a SMN isoform lacking exon 7–which is the predominant isoform produced by the SMN2 gene–to a severe SMA mouse genetic background has moderately beneficial effects on survival [18] . SMNΔ7 SMA mice still display a considerably severe phenotype and die on average at two weeks of age. A mouse model of the mild form of SMA was generated by introducing SMN(A2G), a SMN point mutant found in type III SMA patients, to the severe SMA background [19] . SMN(A2G) SMA mice display very late onset of muscle weakness and motor impairment, moderate loss of motor neurons, and survive over one year. Collectively, these studies indicate that reduced SMN activity causes SMA and that disease severity inversely correlates with SMN levels in both human patients and mouse models. The molecular defect responsible for motor neuron degeneration in SMA is unknown. SMN is a multifunctional protein that has been implicated in a variety of cellular processes, many of which are linked to RNA metabolism [20] , [21] . It is well established that SMN associates with itself and at least eight additional proteins (Gemins2-8 and unrip) to form a macromolecular complex referred to as the SMN complex [22] . To date, the only molecularly defined cellular activity of the SMN complex is its function in the biogenesis of small nuclear ribonucleoproteins (snRNPs), the essential components of the pre-mRNA splicing machinery that catalyze the excision of introns from mRNA precursors in the nucleus. Spliceosomal snRNPs of the Sm class comprise an snRNA molecule (U1, U2, U4, U4atac, U5, U11 and U12), seven common Sm proteins and additional proteins specific for each snRNP [23] . The snRNP biogenesis pathway requires the activity of a number of auxiliary factors and takes place in both the nucleus and the cytoplasm [22] , [23] . In the cytoplasm, the SMN complex mediates the ATP-dependent assembly of a heptameric ring of Sm proteins around a conserved sequence of the snRNAs to form the Sm core [24] – [26] . Consistent with the essential role for the SMN complex in snRNP assembly, reducing expression of either SMN or Gemin proteins in cultured cells affects Sm core formation [27] – [33] . It is, however, becoming increasingly clear that SMN may have additional functions in distinct cell types that are unrelated to snRNP biogenesis and are relevant to SMA [34] – [37] . A subset of SMN complexes that do not contain Sm proteins traffic into axons and growth cones of motor